About Walpar Nutritions
Walpar Nutritions is a publicly listed company based in Gandhinagar (India) founded in 2009 by Divyanshu Raval. Tablets, capsules, and nutraceutical products are manufactured as a CDMO. Its Indian entity Walpar Nutritions Limited reported revenue of ₹79.05 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.
Company details
Walpar Nutritions was founded in 2009 in Gandhinagar, India, as a contract development and manufacturing organization in the nutraceutical sector. Operations center on the production of tablets, capsules, and related products for client specifications. Services include formulation development and scalable manufacturing processes, conducted within facilities in India to meet industry standards. Focus remains on efficient supply chain management for nutraceutical outputs.
- Headquarters Gandhinagar, India
- Founders Divyanshu Raval
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website walparnutritions.com
- Social LinkedIn Facebook Instagram YouTube
- Legal Name Walpar Nutritions Ltd.
- Market Cap₹23.48 Cr
WALPAR-SM · NSE
- Share Price₹25.00
0.00% today
- Revenue₹78.79 Cr
FY 2025-26 · +9.8% YoY
- EBITDA₹6.66 Cr
Margin 8.4%
- Net Profit₹2.48 Cr
FY 2025-26 · +6.4% YoY
- P/E (TTM)9.5x
P/B 1.2x
- ROE18.1%
ROCE 16.3%
- Debt / Equity0.69
Interest cover 17.2x
Associated legal entities of Walpar Nutritions
Walpar Nutritions operates through Walpar Nutritions Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Walpar Nutritions Limited Listed CIN L24230GJ2020PLC118662 | Active | 04 Dec 2020 | Gandhinagar, Gujarat | ₹79.1 Cr | 24 | 11 | View details |
Apps and channels of Walpar Nutritions
its YouTube channel Walpar Nutritions Limited has 94 subscribers and 10 videos.
Videos from Walpar Nutritions
The most watched videos on Walpar Nutritions's YouTube channel, Walpar Nutritions Limited (94 subscribers). Click a video to play it here.
More on Walpar Nutritions Limited.
Board of directors of Walpar Nutritions Limited (Walpar Nutritions)
Walpar Nutritions Limited is the primary company behind Walpar Nutritions. The board of Walpar Nutritions Limited currently have 9 directors; the longest-serving is Tanmaykumar Ashwinbhai Shah, appointed in 2020. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Tanmaykumar Ashwinbhai Shah DIN 08984640 | Whole-time director | 04 Dec 2020 | 5 yrs 10 mo | Walpar Nutritions Limited |
| Kalpesh Pravinchandra Ladhawala DIN 02849232 | Managing Director | 04 Dec 2020 | 5 yrs 10 mo | Walpar Nutritions Limited |
| Sejal Kalpesh Ladhawala DIN 07331231 | Director | 04 Dec 2020 | 5 yrs 10 mo | Walpar Nutritions Limited |
| Nidhi Yogeshkumar Shah DIN 09008374 | Director | 24 Dec 2020 | 5 yrs 10 mo | Walpar Nutritions Limited |
| Fenil Prakashkumar Shah DIN 09012730 | Director | 29 Dec 2020 | 5 yrs 10 mo | Walpar Nutritions Limited |
| Rupesh Himatlal Shah DIN 07911687 | Director | 13 Feb 2021 | 5 yrs 8 mo | Walpar Nutritions Limited |
| Jayshukh Ramjibhai Detroja DIN 09066938 | Director | 13 Feb 2021 | 5 yrs 8 mo | Walpar Nutritions Limited |
| Tapan Natverlal Patel DIN 09066951 | Director | 13 Feb 2021 | 5 yrs 8 mo | Walpar Nutritions Limited |
| Nehalkumar Shah DIN 09066955 | Director | 13 Feb 2021 | 5 yrs 8 mo | Walpar Nutritions Limited |
People of Walpar Nutritions
1 people are tracked at Walpar Nutritions (1 in leadership).
| Name | Role | Group |
|---|---|---|
Divyanshu Raval | Co-Founder | Leadership |
Complete people profiles for Walpar Nutritions
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Walpar Nutritions
Walpar Nutritions is a publicly listed company on the NSE with ticker symbol WALPAR in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Jul 2021
- Listed onNSE: WALPAR
- Listed entityWalpar Nutritions Ltd.
- Exchange sectorHealth technology
- ISININE0G2G01015
- Share price₹26.10 · 2026-10-13
- Volume (last session)2,000
Financials of Walpar Nutritions
Exchange-reported figures of Walpar Nutritions Limited, the listed company behind Walpar Nutritions (NSE: WALPAR-SM).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 78.79 | 71.76 | 62.52 | 35.14 | 26.76 | 6.07 |
| Revenue growth | +9.8% | +14.8% | +77.9% | +31.3% | +340.9% | - |
| EBITDA | 6.66 | 5.72 | 4.75 | 3.47 | 1.01 | 0.45 |
| EBITDA margin | +8.5% | +8.0% | +7.6% | +9.9% | +3.8% | +7.4% |
| Profit before tax | 4.10 | 3.88 | 2.49 | 1.11 | 0.29 | 0.15 |
| Net profit | 2.48 | 2.33 | 1.53 | 0.60 | 0.41 | 0.14 |
| Net profit margin | +3.2% | +3.3% | +2.5% | +1.7% | +1.5% | +2.3% |
| EPS (₹) | 2.64 | 2.48 | 3.37 | 1.30 | 0.84 | 0.45 |
| Balance sheet | ||||||
| Total assets | 38.91 | 27.12 | 24.72 | 23.89 | 19.86 | 12.30 |
| Net worth | 18.90 | 16.56 | 14.19 | 11.71 | 10.99 | 4.78 |
| Total debt | 16.77 | 7.85 | 8.30 | 10.30 | 7.25 | 7.49 |
| Cash & bank | 4.93 | 1.59 | 0.51 | 0.54 | 0.46 | 0.98 |
| Net working capital | 21.55 | 14.20 | 12.21 | 13.19 | 10.59 | 9.09 |
| Cash flow | ||||||
| Cash from operations | 1.83 | 4.06 | 5.35 | 1.10 | (1.08) | (0.31) |
| Cash from investing | (6.57) | (2.30) | (3.61) | (3.44) | (6.14) | (2.02) |
| Cash from financing | 8.08 | (0.68) | (1.77) | 2.42 | 6.71 | 2.95 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 65.30 | 60.16 | 51.31 | 28.70 | 26.76 | 6.07 | 16.71 |
| Revenue growth | +8.5% | +17.3% | +78.8% | +7.3% | +340.9% | -63.7% | - |
| EBITDA | 2.91 | 2.83 | 1.76 | 0.78 | 1.06 | 0.45 | 1.22 |
| EBITDA margin | +4.5% | +4.7% | +3.4% | +2.7% | +4.0% | +7.4% | +7.3% |
| Profit before tax | 2.53 | 2.42 | 1.47 | 0.46 | 0.34 | 0.15 | 0.20 |
| Net profit | 1.98 | 1.68 | 1.06 | 0.30 | 0.44 | 0.14 | 0.13 |
| Net profit margin | +3.0% | +2.8% | +2.1% | +1.1% | +1.6% | +2.3% | +0.8% |
| EPS (₹) | 2.09 | 1.80 | 2.37 | 0.65 | 0.92 | 0.45 | 0.63 |
| Balance sheet | |||||||
| Total assets | 18.89 | 15.02 | 13.65 | 14.52 | 15.41 | 10.24 | 9.11 |
| Net worth | 16.98 | 15.02 | 13.34 | 11.32 | 11.03 | 4.78 | 3.23 |
| Total debt | 1.91 | 0.00 | 0.32 | 3.21 | 4.38 | 5.46 | 5.88 |
| Cash & bank | 0.86 | 1.51 | 0.45 | 0.37 | 0.34 | 0.97 | 0.45 |
| Net working capital | 8.58 | 7.96 | 7.28 | 8.84 | 8.97 | 8.28 | 7.71 |
| Cash flow | |||||||
| Cash from operations | 1.15 | 2.71 | 3.13 | 1.09 | (0.32) | 1.38 | 0.40 |
| Cash from investing | (3.62) | (1.23) | (0.88) | 0.46 | (4.58) | (0.70) | 0.00 |
| Cash from financing | 1.82 | (0.42) | (2.18) | (1.52) | 4.27 | (0.06) | (0.24) |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 78.79 | 71.76 | 62.52 | 35.14 | 26.76 | 6.07 |
| Revenue growth | +9.8% | +14.8% | +77.9% | +31.3% | +340.9% | - |
| Other income | 0.26 | 0.27 | 0.22 | 0.34 | 0.04 | 0.00 |
| Total expenses | 72.13 | 66.04 | 57.77 | 31.67 | 25.75 | 5.62 |
| Employee cost | 6.03 | 3.70 | 3.17 | 3.14 | 2.11 | 0.61 |
| EBITDA | 6.66 | 5.72 | 4.75 | 3.47 | 1.01 | 0.45 |
| EBITDA margin | +8.5% | +8.0% | +7.6% | +9.9% | +3.8% | +7.4% |
| Depreciation | 2.02 | 1.82 | 1.81 | 1.91 | 0.28 | 0.12 |
| Interest | 0.80 | 0.29 | 0.67 | 0.79 | 0.48 | 0.18 |
| Profit before tax | 4.10 | 3.88 | 2.49 | 1.11 | 0.29 | 0.15 |
| Tax | 0.89 | 1.08 | 0.55 | 0.30 | (0.09) | 0.01 |
| Net profit | 2.48 | 2.33 | 1.53 | 0.60 | 0.41 | 0.14 |
| Net profit margin | +3.2% | +3.3% | +2.5% | +1.7% | +1.5% | +2.3% |
| EPS (₹) | 2.64 | 2.48 | 3.37 | 1.30 | 0.84 | 0.45 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 9.39 | 9.39 | 4.70 | 4.54 | 4.54 | 3.34 |
| Reserves & surplus | 9.51 | 7.17 | 9.49 | 7.17 | 6.45 | 1.44 |
| Shareholders' funds (net worth) | 18.90 | 16.56 | 14.19 | 11.71 | 10.99 | 4.78 |
| Minority interest | 3.24 | 2.72 | 2.24 | 1.88 | 1.61 | 0.03 |
| Secured loans | 15.10 | 6.95 | 6.54 | 7.86 | 4.64 | 2.75 |
| Unsecured loans | 1.67 | 0.90 | 1.76 | 2.44 | 2.61 | 4.74 |
| Total debt | 16.77 | 7.85 | 8.30 | 10.30 | 7.25 | 7.49 |
| Total liabilities | 38.91 | 27.12 | 24.72 | 23.89 | 19.86 | 12.30 |
| Assets | ||||||
| Gross block | 20.72 | 17.15 | 14.88 | 13.03 | 2.41 | 1.82 |
| Net block | 12.21 | 10.65 | 10.20 | 10.13 | 2.01 | 1.70 |
| Capital work in progress | 0.05 | 0.03 | 0.02 | 0.02 | 4.48 | 1.22 |
| Investments | 2.88 | 1.88 | 1.88 | 0.02 | 0.49 | 0.00 |
| Inventories | 15.26 | 10.53 | 9.16 | 8.50 | 5.93 | 4.33 |
| Sundry debtors | 23.45 | 21.18 | 13.44 | 12.48 | 9.11 | 7.16 |
| Cash & bank balances | 4.93 | 1.59 | 0.51 | 0.54 | 0.46 | 0.98 |
| Loans & advances | 5.06 | 1.15 | 1.54 | 2.08 | 3.32 | 2.32 |
| Total current assets | 48.70 | 34.45 | 24.65 | 23.60 | 18.82 | 14.79 |
| Total current liabilities | 27.15 | 20.25 | 12.44 | 10.41 | 8.23 | 5.70 |
| Net working capital | 21.55 | 14.20 | 12.21 | 13.19 | 10.59 | 9.09 |
| Total assets | 38.91 | 27.12 | 24.72 | 23.89 | 19.86 | 12.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 1.59 | 0.51 | 0.54 | 0.46 | 0.98 | 0.35 |
| Net cash from operating activities | 1.83 | 4.06 | 5.35 | 1.10 | (1.08) | (0.31) |
| Net cash from investing activities | (6.57) | (2.30) | (3.61) | (3.44) | (6.14) | (2.02) |
| Net cash from financing activities | 8.08 | (0.68) | (1.77) | 2.42 | 6.71 | 2.95 |
| Net change in cash | 3.34 | 1.08 | (0.03) | 0.07 | (0.51) | 0.62 |
| Closing cash | 4.93 | 1.59 | 0.51 | 0.54 | 0.46 | 0.98 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +9.8% | +14.8% | +77.9% | +31.3% | +340.9% | - |
| EBITDA growth | +16.4% | +20.4% | +36.9% | +243.6% | +124.4% | - |
| PBT growth | +5.7% | +55.8% | +124.3% | +282.8% | +93.3% | +9997.0% |
| Net income growth | +6.4% | +52.3% | +155.0% | +46.3% | +192.9% | - |
| Revenue CAGR (3Y) | +30.9% | +38.9% | +117.6% | - | - | - |
| EBITDA CAGR (3Y) | +24.3% | +78.3% | +119.4% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +4.1% | +3.9% | +3.1% | +2.3% | +1.4% | +2.3% |
| Return on capital employed | +16.3% | +17.8% | +14.3% | +9.4% | +5.0% | +2.8% |
| Return on net worth | +18.1% | +18.2% | +15.1% | +7.1% | +4.6% | +3.1% |
| Debt / equity | 0.69 | 0.53 | 0.72 | 0.77 | 0.93 | 1.57 |
| Long-term debt / equity | 0.37 | 0.27 | 0.39 | 0.34 | 0.40 | 0.97 |
| Interest cover | 17.24 | 7.44 | 22.79 | 50.64 | 65.75 | 54.55 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 4.16 | 4.48 | 4.48 | 4.55 | 12.65 | 3.34 |
| Inventory turnover | 6.11 | 7.29 | 7.08 | 4.87 | 5.22 | 1.40 |
| Debtors turnover | 3.53 | 4.15 | 4.82 | 3.26 | 3.29 | 0.85 |
| EPS (₹) | 2.64 | 2.48 | 3.37 | 1.30 | 0.84 | 0.45 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 20.13 | 17.63 | 30.21 | 25.80 | 24.21 | 14.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 65.30 | 60.16 | 51.31 | 28.70 | 26.76 | 6.07 | 16.71 |
| Revenue growth | +8.5% | +17.3% | +78.8% | +7.3% | +340.9% | -63.7% | - |
| Other income | 0.14 | 0.10 | 0.13 | 0.27 | 0.04 | 0.00 | 0.00 |
| Total expenses | 62.39 | 57.33 | 49.55 | 27.92 | 25.70 | 5.62 | 15.49 |
| Employee cost | 0.90 | 1.03 | 0.97 | 0.96 | 2.11 | 0.61 | 2.56 |
| EBITDA | 2.91 | 2.83 | 1.76 | 0.78 | 1.06 | 0.45 | 1.22 |
| EBITDA margin | +4.5% | +4.7% | +3.4% | +2.7% | +4.0% | +7.4% | +7.3% |
| Depreciation | 0.43 | 0.41 | 0.21 | 0.25 | 0.28 | 0.12 | 0.29 |
| Interest | 0.09 | 0.10 | 0.21 | 0.34 | 0.48 | 0.18 | 0.73 |
| Profit before tax | 2.53 | 2.42 | 1.47 | 0.46 | 0.34 | 0.15 | 0.20 |
| Tax | 0.55 | 0.74 | 0.36 | 0.16 | (0.09) | 0.01 | 0.07 |
| Net profit | 1.98 | 1.68 | 1.06 | 0.30 | 0.44 | 0.14 | 0.13 |
| Net profit margin | +3.0% | +2.8% | +2.1% | +1.1% | +1.6% | +2.3% | +0.8% |
| EPS (₹) | 2.09 | 1.80 | 2.37 | 0.65 | 0.92 | 0.45 | 0.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 9.39 | 9.39 | 4.70 | 4.54 | 4.54 | 3.34 | 3.00 |
| Reserves & surplus | 7.59 | 5.63 | 8.64 | 6.78 | 6.49 | 1.44 | 0.23 |
| Shareholders' funds (net worth) | 16.98 | 15.02 | 13.34 | 11.32 | 11.03 | 4.78 | 3.23 |
| Secured loans | 1.91 | 0.00 | 0.32 | 1.95 | 1.81 | 2.75 | 0.75 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 1.26 | 2.57 | 2.71 | 5.13 |
| Total debt | 1.91 | 0.00 | 0.32 | 3.21 | 4.38 | 5.46 | 5.88 |
| Total liabilities | 18.89 | 15.02 | 13.65 | 14.52 | 15.41 | 10.24 | 9.11 |
| Assets | |||||||
| Gross block | 4.18 | 3.52 | 2.30 | 1.48 | 1.34 | 1.18 | 2.13 |
| Net block | 2.52 | 2.29 | 1.48 | 0.83 | 0.94 | 1.06 | 1.14 |
| Capital work in progress | 0.05 | 0.03 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Investments | 5.06 | 4.70 | 4.70 | 2.84 | 2.93 | 0.06 | 0.00 |
| Inventories | 7.58 | 4.77 | 5.03 | 6.04 | 5.93 | 4.33 | 4.03 |
| Sundry debtors | 19.91 | 16.95 | 10.09 | 8.78 | 9.11 | 7.16 | 8.39 |
| Cash & bank balances | 0.86 | 1.51 | 0.45 | 0.37 | 0.34 | 0.97 | 0.45 |
| Loans & advances | 1.27 | 0.62 | 1.56 | 0.98 | 1.53 | 1.27 | 0.28 |
| Total current assets | 29.62 | 23.85 | 17.13 | 16.17 | 16.91 | 13.73 | 13.15 |
| Total current liabilities | 21.04 | 15.89 | 9.85 | 7.33 | 7.94 | 5.45 | 5.44 |
| Net working capital | 8.58 | 7.96 | 7.28 | 8.84 | 8.97 | 8.28 | 7.71 |
| Total assets | 18.89 | 15.02 | 13.65 | 14.52 | 15.41 | 10.24 | 9.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.51 | 0.45 | 0.37 | 0.34 | 0.97 | 0.35 | 0.28 |
| Net cash from operating activities | 1.15 | 2.71 | 3.13 | 1.09 | (0.32) | 1.38 | 0.40 |
| Net cash from investing activities | (3.62) | (1.23) | (0.88) | 0.46 | (4.58) | (0.70) | 0.00 |
| Net cash from financing activities | 1.82 | (0.42) | (2.18) | (1.52) | 4.27 | (0.06) | (0.24) |
| Net change in cash | (0.65) | 1.06 | 0.07 | 0.03 | (0.63) | 0.62 | 0.17 |
| Closing cash | 0.86 | 1.51 | 0.45 | 0.37 | 0.34 | 0.97 | 0.45 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +8.5% | +17.3% | +78.8% | +7.3% | +340.9% | -63.7% | - |
| EBITDA growth | +2.8% | +60.8% | +125.6% | -26.4% | +135.6% | -63.1% | - |
| PBT growth | +4.6% | +64.6% | +219.6% | +35.3% | +126.7% | +9997.0% | +9997.0% |
| Net income growth | +17.9% | +58.5% | +253.3% | -31.8% | +214.3% | +7.7% | - |
| Revenue CAGR (3Y) | +31.5% | +31.0% | +103.7% | +171.8% | +25.4% | - | - |
| EBITDA CAGR (3Y) | +55.1% | +38.7% | +57.6% | +27.1% | -6.5% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +3.0% | +2.8% | +2.2% | +1.1% | +1.6% | +2.3% | +0.8% |
| Return on capital employed | +15.4% | +17.6% | +12.0% | +5.3% | +6.4% | +3.3% | +12.3% |
| Return on net worth | +12.3% | +11.9% | +9.0% | +2.6% | +5.3% | +3.1% | +6.2% |
| Debt / equity | 0.06 | 0.01 | 0.14 | 0.34 | 0.62 | 1.14 | 2.88 |
| Long-term debt / equity | 0.00 | 0.00 | 0.04 | 0.12 | 0.27 | -0.06 | 1.37 |
| Interest cover | 3.63 | 4.13 | 13.55 | 64.15 | 61.54 | 54.55 | 78.49 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 16.96 | 20.67 | 27.15 | 20.35 | 21.24 | 5.14 | 8.94 |
| Inventory turnover | 10.57 | 12.28 | 9.27 | 4.80 | 5.22 | 1.40 | 4.40 |
| Debtors turnover | 3.54 | 4.45 | 5.44 | 3.21 | 3.29 | 0.85 | 2.27 |
| EPS (₹) | 2.09 | 1.80 | 2.37 | 0.65 | 0.92 | 0.45 | 0.63 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 18.08 | 15.99 | 28.40 | 24.92 | 24.29 | 14.30 | 10.00 |
Similar companies to Walpar Nutritions
Walpar Nutritions has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | Company offering a suite of R&D and manufacturing services for small molecules and generics | |||
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. |
Detailed similar companies of Walpar Nutritions
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Walpar Nutritions
The website of Walpar Nutritions (walparnutritions.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 68% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Walpar Nutritions (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Walpar Nutritions
Complete news archive for Walpar Nutritions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Walpar Nutritions
Walpar Nutritions was founded in 2009.
Walpar Nutritions is headquartered in Gandhinagar, India. It is registered at Gandhinagar, Gujarat, India.
The primary company behind Walpar Nutritions, Walpar Nutritions Limited, reported revenue of ₹79.05 Cr for FY 2026, up 10% year on year.
Walpar Nutritions was founded in 2009 in Gandhinagar, India, as a contract development and manufacturing organization in the nutraceutical sector. Operations center on the production of tablets, capsules, and related products for client specifications. Services include formulation development and scalable manufacturing processes, conducted within facilities in India to meet industry standards. Focus remains on efficient supply chain management for nutraceutical outputs.
Walpar Nutritions's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Yes, Walpar Nutritions is publicly traded on NSE under the ticker symbol WALPAR.
Walpar Nutritions operates through Walpar Nutritions Limited.
The legal entities of Walpar Nutritions currently have 10 directors, including Tanmaykumar Ashwinbhai Shah, Kalpesh Pravinchandra Ladhawala, Nidhi Yogeshkumar Shah and others.